

Sodium and barium cation-templated synthesis and cation-induced molecular pirouetting of a pyridine *N*-oxide containing [2]rotaxane

Supplementary Information

*Laura M. Hancock and Paul D. Beer**

Inorganic Chemistry Laboratory, Department of Chemistry
University of Oxford
South Parks Road, Oxford, OX1 3QR (UK)
Fax: (+44) 01865-272690
E-mail: paul.beer@chem.ox.ac.uk

PART I: SYNTHESIS AND CHARACTERISATION	S1
Experimental Details	S1
¹H and ¹³C Spectra of compound 2 and 4	S5
Compound 2	S5
Compound 4	S6
PART II: SULFATE ABSTRACTION OF BARIUM CATIONS	S7
PART III: REFERENCES	S7


PART I: SYNTHESIS AND CHARACTERISATION

General Considerations. Commercially available solvents and chemicals were used without further purification unless stated. Where dry solvents were used, they were degassed with nitrogen, dried by passing through an MBraun MPSP-800 column and then used immediately. Water was deionized and microfiltered using a Milli-Q Millipore machine.


¹H and ¹³C spectra were recorded on a Varian Mercury-VX 300 spectrometer and AVII 500 (for ¹³C cryoprobe). Mass spectrometry was carried out on a Bruker micrOTOF spectrometer.

The synthesis of macrocycle **1**,¹ stopper **3**,¹ **S1** (5-(methoxycarbonyl)nicotinic acid),² and stopper **S2**³ are reported elsewhere. Compound **S5** and pyridine *N*-oxide precursor were prepared according to Schemes S1 and S2 respectively.

Experimental Details



Scheme S1. Synthesis of Compound **S5**.



Scheme S2. Synthesis of pyridine *N*-oxide precursor **2**.

S3:

5-(methoxycarbonyl)nicotinic acid (**S1**) (0.2 g, 1.11 mmol) was suspended in dry CH₂Cl₂ (30 mL), oxalyl chloride (0.19 mL, 2.22 mmol) and DMF (cat.) were added, and the mixture stirred under N_{2(g)} for 1 h until homogenous. The solvent was removed *in vacuo*, the residue dissolved in dry CH₂Cl₂ (20 mL) and added dropwisely to a solution of **S2** (0.52 g, 1.16 mmol), Et₃N (0.28 mL, 2.0 mmol) and DMAP (cat.) in dry CH₂Cl₂ (30 mL). The resulting solution was stirred for 1 h, washed with 10% HCl_(aq) (2 × 50 mL) and H₂O (2 × 50 mL), dried over anhydrous MgSO₄ and the solvent removed *in vacuo*. The resulting brown oil was purified by column chromatography (silica; 95:5 CH₂Cl₂: MeOH) to yield an oily cream coloured solid (0.60 g, 89%).

¹H NMR (300MHz, CDCl₃) δ: 9.34-9.62 (2H, m, pyridine *H*² & *H*⁶), 8.78 (1H, t, ⁴*J* = 2.1 Hz, pyridine *H*⁴), 8.05 (1H, br s, ArNH), 7.55 (2H, d, ³*J* = 8.9 Hz, ArHNH), 7.11 – 7.28 (17H, m, ArH), 4.02 (3H, s, CH₃), 1.31 (18H, s, ^tBu); ¹³C NMR (300MHz, CDCl₃) δ: 164.9, 162.8, 152.9, 151.9, 148.5, 146.9, 144.3, 143.5, 135.9, 134.9, 131.9, 131.1, 130.6, 127.3, 125.8, 124.3, 119.3, 63.8, 34.3, 33.3; HRMS (ESI): *m/z* calc. for C₄₁H₄₂N₂O₃ [M + Na]⁺: 633.3088; found 633.3091.

S4:

S3 (1.81 g, 2.96 mmol) was dissolved in 1:1 THF/H₂O (50 mL), KOH (0.196 g, 3.5 mmol) was added, and the solution stirred for 16 h. 10% citric acid_(aq) was added until the solution was pH = 7, and the aqueous mixture extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were dried over anhydrous MgSO₄, and the solvent removed *in vacuo*. The resulting sticky brown solid was recrystallized from CHCl₃ to give an off-white solid (1.77 g, 100%).

¹H NMR (300MHz, *d*₆-DMSO) δ: 11.70 (1H, s, COOH), 10.63 (1H, s, ArNH), 9.27 (1H, d, ⁴J = 2.0 Hz, pyridine H²), 9.21 (1H, d, ⁴J = 2 Hz, pyridine H⁶), 8.74 (1H, t, ⁴J = 2 Hz, pyridine H⁴), 7.68 (2H, d, ³J = 8.8 Hz, ArHNH), 7.10 – 7.34 (17H, m, ArH), 1.26 (18H, s, *t*Bu); ¹³C NMR (300MHz, *d*₆-DMSO) δ: 165.8, 163.1, 152.3, 147.9, 146.9, 143.6, 142.5, 136.4, 136.0, 130.7, 130.4, 130.1, 127.7, 126.4, 125.8, 124.5, 119.6, 34.9, 31.1; **HRMS (ESI):** *m/z* calc. for C₄₀H₄₀N₂O₃ [M – H]⁺: 596.2966; found: 595.2980.

S5:

4,4'-bis(azidomethyl)biphenyl (**S5**) (300 mg, 1.14 mmol) was dissolved in 1:1 Et₂O/EtOAc (10 mL), 5% HCl_(aq) (20 mL) was added and the biphasic mixture cooled to 0 °C. A solution of Ph₃P (295 mg, 1.13 mmol) in 1:1 Et₂O/EtOAc (10 mL) was added dropwise over 30 min, and the solution stirred for 18 h at RT. The precipitate was collected by vacuum filtration and washed with 1:1 Et₂O/EtOAc (2 x 50 mL). The resulting solid was suspended in CH₂Cl₂, 10% NaOH_(aq) added and the biphasic mixture stirred for 30 min until all solid had dissolved. The organic layer was separated, washed with H₂O (2 x 50 mL), dried over MgSO₄, and the solvent removed *in vacuo* to give a white waxy solid (100 mg, 37%).

¹H NMR (300 MHz, CD₃OD) δ: 7.59 – 7.66 (4H, m, ArH), 7.42 (4H, d, ³J = 8.2 Hz, ArH), 4.40 (2H, s, CH₂N₃), 3.83 (2H, s, CH₂NH₂); ¹³C NMR (75.5 MHz, CD₃OD) δ: 142.6, 141.9, 140.3, 135.9, 129.8, 128.9, 128.1, 128.0, 55.1, 46.2. **HRMS (Probe FI)** calculated for C₁₄H₁₄N₄ [M]⁺: 238.1218; found 238.1212.

S6:

S4 (192 mg, 1.06 mmol) was suspended in dry CH₂Cl₂ (20 mL), then oxalyl chloride (0.190 mL, 2.12 mmol) and DMF (cat.) were added. The mixture was stirred for 1 h until all solid had dissolved. The solvent was removed *in vacuo*, then redissolved in dry CH₂Cl₂ (15 mL) and added dropwise to a solution of compound **S5** (253 mg, 1.06 mmol) and Et₃N (0.42 mL, 3 mmol) in CH₂Cl₂ (20 mL). The resulting solution was stirred for 1 h, washed with 10 % HCl_(aq) (2 x 50 mL) and H₂O (2 x 50 mL), dried over anhydrous MgSO₄, and the solvent removed *in vacuo*. The resulting brown oil was purified by column chromatography (silica; 95:5 CH₂Cl₂/MeOH) giving an oily orange solid (306 mg, 72 %).

¹H NMR (300 MHz, CDCl₃) δ: 9.34 (1H, s, pyridine H²), 9.26 (1H, s, pyridine H⁶), 8.69 (1H, s, pyridine H⁴), 7.61 (4H, d, ³J = 8.2 Hz, ArH), 7.47 (2H, d, ³J = 8.2 Hz, ArH), 7.41 (2H, d, ³J = 8.2 Hz, ArH), 6.61 (1H, br s, NH), 4.72 (2H, d, ³J = 5.9 Hz, NHCH₂), 4.40 (2H, s, CH₂N₃), 3.99 (3H, s, OCH₃); ¹³C NMR

(75.5 MHz, CDCl₃) δ : 164.9, 164.4, 153.0, 151.9, 140.5, 140.2, 136.7, 135.7, 134.6, 129.8, 128.7, 128.6, 127.6, 127.5, 125.9, 54.5, 52.7, 44.0; **HRMS (ESI)** m/z calc. for C₅₄H₅₂N₆O₂ [M + Na]⁺: 839.4044; found: 839.4038.

Pyridine *N*-oxide axle precursor (2):

Compound **S5** (0.198 g, 0.24 mmol) and NaHCO₃ (1.03 g, 7.26 mmol) were dissolved in 1:1 2-butanone/H₂O (50 mL) and a saturated solution of Oxone[®] (0.446 g, 0.726 mmol) in H₂O (3 mL) was added dropwisely. The solution was stirred vigorously for 2 h before addition of NaCl (1.70 g, 29.0 mmol) and extraction with CHCl₃ (3 × 50 mL). The organic layer was dried over anhydrous MgSO₄ and the solvent removed *in vacuo* to give a white solid (0.196 g, 97%).

¹H NMR (300MHz, CDCl₃) δ (ppm): 9.71 (1H, s, ArH_{NH}), 8.88 (1H, s, pyridine H⁶), 8.84 (1H, s, pyridine H²), 8.38 (2H, br s, CH₂NH & pyridine H⁴), 7.63 (2H, d, ³J = 8.8 Hz, ArH_{NH}), 7.55 (2H, d, ³J = 8.2 Hz, biphenyl ArH), 7.49 (2H, d, ³J = 8.2 Hz, biphenyl ArH), 7.15 – 7.35 (19H, m, stopper ArH), 4.53 (2H, d, ³J = 4.7 Hz, CH₂NH), 4.35 (2H, s, CH₂N₃), 1.36 (18H, s, ^tBuH) ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 162.0, 160.4, 148.5, 146.9, 144.5, 143.5, 140.2, 139.8, 136.3, 135.0, 134.5, 133.6, 131.8, 131.0, 130.6, 128.6, 128.3, 127.4, 127.3, 127.2, 125.8, 124.3, 119.5, 63.8, 54.4, 44.0, 34.3, 31.3. **HRMS (ESI)**: m/z calc. for C₅₄H₅₂N₆O₃ [M + Na]⁺: 855.3993; found: 855.3994.

Calixdiquinone *N*-oxide rotaxane (4):

General procedure: calixdiquinone macrocycle **1** (30 mg, 0.0285 mmol), compound **2** (24 mg, 0.0285 mmol), and stopper **3** (14 mg, 0.0285 mmol) were dissolved in degassed CH₂Cl₂ (20 mL), (a solution of M(ClO₄)_x (0.0285mmol) in) CH₃CN (0.25 mL) was added and the solution stirred for 15 min. DIPEA (5 μ L, 0.0293 mmol) and Cu(CH₃CN)₄PF₆ (2 mg, 0.0054 mmol) were added and the solution stirred under N₂ for 16 h. The solvent was removed *in vacuo* and the crude material purified by preparative TLC (silica; 1:1 acetone/hexane & CH₃CN → 93:7 CH₃CN/MeOH) to obtain a yellow solid.

Without cation: Neat CH₃CN added i.e. no M(ClO₄)_x, giving a yield of 10% (7 mg).

With Barium: M = Ba x = 2, giving a yield of 28% (18 mg). N.B. Ba(ClO₄)₂ mostly suspended throughout reaction

With Sodium: M = Na, x = 1, giving a yield of 50% (34 mg).

¹H NMR (300MHz, CDCl₃) δ (ppm): 9.12 (1H, s, axle ArH_{NH}), 8.68 (2H, s, pyridine H⁶ & isophthalamide H²), 8.54 (1H, s, pyridine H²), 8.52 (1H, t, ³J = 5.6 Hz, axle CH₂NH), 8.39 (2H, br s, macrocycle NH), 8.23 (2H, dd, ³J = 7.9 Hz, ⁴J = 1.9 Hz, isophthalamide H⁴ & H⁶), 8.03 (1H, s, pyridine H⁴), 7.92 (2H, d, ³J = 8.8 Hz, ArH_{NH}), 7.64 (1H, s, triazole, CH), 7.59 (2H, d, ³J = 7.5 Hz, biphenyl ArH), 7.50 (2H, d, ³J = 8.2 Hz, biphenyl ArH), 7.37 – 7.41 (4H, m, biphenyl ArH), 7.06 – 7.29 (31H, m, isophthalamide H⁵ & stopper ArH), 6.85 (2H, d, ³J = 8.8 Hz, ArHOCH₂), 6.55 – 6.56 (4H, m, calix ArH), 6.50 (4H, d, ³J = 9.1 Hz, hydroquinone ArH), 6.32 – 6.37 (8H, m, calix & hydroquinone ArH), 5.60 (2H,

s, axle OCH_2), 5.17 (2H, s, CH_2N), 4.59 (2H, d, $^3J = 5.6$ Hz, axle CH_2NH), 4.29 (2H, d, $^2J = 12.9$ Hz, calix CH_2), 4.21 (2H, t, $^3J = 8.7$ Hz, macrocycle CH_2), 4.09 (2H, d, $^2J = 12.9$ Hz, calix CH_2) 3.96 – 3.99 (2H, m, macrocycle CH_2), 3.89 – 3.94 (6H, m, macrocycle CH_2), 3.82 – 3.85 (2H, m, macrocycle CH_2), 3.71 – 3.77 (4H, m, macrocycle CH_2), 2.92 (2H, $^2J = 12.9$ Hz, calix CH_2), 2.73 (2H, $^2J = 12.9$ Hz, calix CH_2), 1.32 (18H, s, axle ^tBu), 1.29 (18H, s, axle ^tBu), 0.95 (18H, s, calix ^tBu); ^{13}C NMR (125 MHz, CDCl_3) δ (ppm): 187.9, 187.5, 185.0, 184.9, 167.9, 167.8, 161.6, 159.4, 156.4, 153.3, 152.8, 152.0, 149.0, 148.7, 148.2, 148.0, 147.5, 147.3, 147.0, 145.0, 144.4, 144.1, 143.5, 141.3, 140.9, 140.3, 140.2, 139.7, 137.9, 136.2, 134.1, 134.0, 132.5, 132.2, 132.1, 131.8, 131.4, 131.2, 130.9, 130.8, 129.5, 129.4, 129.2, 129.0, 128.0, 127.7, 127.7, 127.5, 127.0, 126.3, 125.9, 125.4, 125.3, 124.9, 124.7, 124.5, 124.4, 122.9, 118.7, 115.4, 114.2, 113.5, 74.4, 67.7, 67.0, 634.0, 63.7, 62.3, 54.2, 53.7, 43.4, 41.0, 34.6, 34.5, 34.2, 31.6, 31.6, 31.4. **HRMS (ESI):** m/z calc. for $\text{C}_{154}\text{H}_{154}\text{N}_8\text{O}_{16} [\text{M} + \text{Na}]^+$: 2395.1414; found 2395.1450

^1H and ^{13}C spectra of Compounds 2 and 4

Compound 2




Figure S1. ^1H NMR spectrum of **2** (CDCl_3 , 300 MHz, 293 K)




Figure S2. ^{13}C NMR spectrum of **2** (CDCl_3 , 75.5 MHz, 293 K)

Compound 4




Figure S3. ^1H NMR spectrum of **4** (CDCl_3 , 300 MHz, 293 K)




Figure S4. ^{13}C NMR spectrum of **4** (CDCl_3 , 125 MHz, 293 K)

PART II: SULFATE ABSTRACTION OF BARIUM CATION




Figure S5. Partial ^1H NMR spectra in 5:1 $\text{CDCl}_3/\text{CD}_3\text{CN}$ of (a) rotaxane **4**, (b) rotaxane **4** + 1 eq. $\text{Ba}(\text{ClO}_4)_2$ and (c) rotaxane **4** + 1 eq. $\text{Ba}(\text{ClO}_4)_2$ + 1 eq. $(\text{TBA})_2\text{SO}_4$.

PART III: REFERENCES

1. A. V. Leontiev, C. A. Jemmett and P. D. Beer, *Chem. Eur. J.*, 2011, **17**, 816-825.
2. K. M. Broadus and S. R. Kass, *J. Am. Chem. Soc.*, 2000, **122**, 9014-9018.
3. H. W. Gibson, S.-H. Lee, P. T. Engen, P. Lecavalier, J. Sze, Y. X. Shen and M. Bheda, *J. Org. Chem.*, 1993, **58**, 3748-3756.